Bortezomib: all 701 studies that test it

Page 2 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior TreatmentTerminatedNCT01548573Phase 2Results posted
• Velcade (Bortezomib) Consolidation After TransplantCompletedNCT01539083Phase 3Results posted
• Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom MacroglobulinemiaTerminatedNCT01536067Phase 2Results posted
• Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive GenotypeCompletedNCT01534260Phase 1/2Results posted
• High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01534143Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
• Panitumumab and Bortezomib for Patients With Advanced Colorectal CancerTerminatedNCT01504477Phase 1/2Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTerminatedNCT01465386Phase 2Results posted
• Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant MelanomaCompletedNCT01462773Phase 1Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01453101Phase 2Results posted
• Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or OlderTerminatedNCT01453088Phase 2Results posted
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple MyelomaTerminatedNCT01438177Phase 2Results posted
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01420926Phase 2Results posted
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT01415752Phase 2Results posted
• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01371981Phase 3Results posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney TransplantationTerminatedNCT01349595Phase 2Results posted
• Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related DonorsCompletedNCT01323920Phase 2Results posted
• Bortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaTerminatedNCT01315873Phase 2Results posted
• UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaCompletedNCT01313897Phase 2Results posted
• Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01312818Phase 2Results posted
• Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin LymphomaCompletedNCT01286272Phase 2Results posted
• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2Results posted
• Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01281917Phase 2Results posted
• Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCompletedNCT01267812Phase 2Results posted
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTCompletedNCT01242267Phase 1/2Results posted
• Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple MyelomaCompletedNCT01241708Phase 3Results posted
• Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaCompletedNCT01216683Phase 2Results posted
• Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaTerminatedNCT01177683Phase 1/2Results posted
• A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHDTerminatedNCT01163786Phase 2Results posted
• Trial of Three Stem Cell Mobilization Regimens for Multiple MyelomaCompletedNCT01146834Phase 3Results posted
• Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerCompletedNCT01142401Phase 2Results posted
• Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaTerminatedNCT01125293Phase 1/2Results posted
• Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After RituximabTerminatedNCT01119794Phase 2Results posted
• Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)CompletedNCT01109004Phase 3Results posted
• Pilot Study of Velcade® in IgA NephropathyCompletedNCT01103778Phase 4Results posted
• Velcade and Sorafenib in Unresected or Metastatic Renal Cell CarcinomaTerminatedNCT01100242Phase 2Results posted
• Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple MyelomaCompletedNCT01090921Phase 2Results posted
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 2Results posted
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisCompletedNCT01083316Phase 2Results posted
• Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain AmyloidosisCompletedNCT01078454Phase 3Results posted
• Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisCompletedNCT01072773Phase 2Results posted
• A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01063907Phase 1/2Results posted
• Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01062230Phase 2Results posted
• Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
• Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyTerminatedNCT01056601Phase 2Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01040871Phase 2Results posted
• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01034553Phase 1/2Results posted
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
• IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma PatientsCompletedNCT01009840Phase 2Results posted
• EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedNCT01000285Phase 1/2Results posted
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00998010Phase 2Results posted
• Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaCompletedNCT00992446Phase 2Results posted
• Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & TemozolomideCompletedNCT00990652Phase 2Results posted
• A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)CompletedNCT00985959Phase 1Results posted
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted
• Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma PatientsTerminatedNCT00983346Phase 2Results posted
• Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaCompletedNCT00980395Phase 2Results posted
• Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of TherapyCompletedNCT00972959Phase 2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.CompletedNCT00967369Phase 2Results posted
• Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
• Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00937495Phase 2Results posted
• Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma PatientsCompletedNCT00931918Phase 2Results posted
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)TerminatedNCT00923247Phase 1/2Results posted
• Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00920855Phase 1/2Results posted
• A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminatedNCT00920556Phase 2Results posted
• Desensitization in Kidney TransplantationCompletedNCT00908583Phase 4Results posted
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00873093Phase 2Results posted
• Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisordersTerminatedNCT00869323Phase 2Results posted
• Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00863369Phase 1/2Results posted
• Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)CompletedNCT00858234Phase 1Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentTerminatedNCT00851552Phase 2Results posted
• Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With RituximabTerminatedNCT00850499Phase 2Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple MyelomaTerminatedNCT00849251Phase 1/2Results posted
• Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell TransplantCompletedNCT00839956Phase 2Results posted
• A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose ChemotherapyCompletedNCT00833560Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaTerminatedNCT00818649Phase 2Results posted
• Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host DiseaseCompletedNCT00815919Phase 2Results posted
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
• Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung CancerCompletedNCT00798720Phase 2Results posted
• Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyTerminatedNCT00793650Phase 1/2Results posted
• Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaCompletedNCT00793572Phase 2Results posted
• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
• Low Dose Melphalan and Bortezomib for AML and High-Risk MDSCompletedNCT00789256Not applicableResults posted
• Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaCompletedNCT00784823Phase 1/2Results posted
• Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)CompletedNCT00773838Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
• Randomized Trial for Mixed Acute RejectionCompletedNCT00771875Phase 2Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
• Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00742625Phase 1/2Results posted
• Bortezomib With Melphalan and Prednisone for Multiple MyelomaCompletedNCT00734149Phase 2Results posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted

← Bortezomib overview